Antimicrobial stewardship in immunocompromised hosts

Lilian M Abbo; Ella J Ariza-Heredia

doi:10.1016/j.idc.2014.01.008

Antimicrobial stewardship in immunocompromised hosts

Infect Dis Clin North Am. 2014 Jun;28(2):263-79. doi: 10.1016/j.idc.2014.01.008.

Authors

Lilian M Abbo¹, Ella J Ariza-Heredia²

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, Suite 851, Miami, FL 33136, USA. Electronic address: labbo@med.miami.edu.
² Division of Infectious Diseases, Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1460, Houston, TX 77030, USA.

PMID: 24857392
DOI: 10.1016/j.idc.2014.01.008

Abstract

The global spread of antimicrobial resistance has limited the availability of antimicrobial agents to treat infections that affect immunocompromised hosts. Efforts to optimize the selection, dosing, and duration of antimicrobial therapy to improve patient outcomes and minimize selective pressure on antimicrobial resistance are relevant to immunocompromised patients. Collaborative efforts between health care providers with expertise in the diagnosis and treatment of patients with various degrees of immunosuppression are pivotal for the success of antimicrobial stewardship programs in immunocompromised patients.

Keywords: Antimicrobial stewardship; Fever; Hematologic malignancies; Immunocompromised; Neutropenia; Solid organ; Transplant.

Publication types

Review

MeSH terms

Anti-Infective Agents / therapeutic use*
Communicable Diseases / diagnosis
Communicable Diseases / drug therapy*
Diagnostic Tests, Routine / methods
Drug Resistance, Multiple*
Drug Utilization / standards*
Early Diagnosis
Guideline Adherence / standards
Humans
Immunocompromised Host*
Inappropriate Prescribing / prevention & control*

Substances

Anti-Infective Agents